ACE and HLA Genotypes Predict Severity and Disease Progression in Danish Sarcoid Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04462068

Enrollment

150

Registered

2020-07-08

Start date

2019-12-01

Completion date

2023-11-30

Last updated

2024-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoidosis

Brief summary

Sarcoidosis is a multisystem granulomatous disease of unknown cause histologically characterized by noncaseating granulomas. Genetic factors affect disease course, which is highly variable and difficult to predict. This study aims to evaluate the predictive value of ACE and HLA genotypes on disease severity and progression in Danish patients with sarcoidosis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of sarcoidosis * Signed informed consent

Exclusion criteria

* Inability or unwillingness to adhere to the study * Inability to give informed consent

Design outcomes

Primary

Measure	Time frame	Description
Time to initiation of treatment	1 year from diagnosis	Time to initiation of systemic immunosuppression for sarcoidosis

Secondary

Measure	Time frame	Description
Number of participants with extrapulmonary organ involvement	1 year from diagnosis	Number of participants diagnosed with extrapulmonary organ involvement
Change in FEV1	1 year	Increase/ decline/ no change in FEV1
Change in FVC	1 year	Increase/ decline/ no change in FVC
Change in diffusion capacity	1 year	Increase/ decline/ no change in diffusion capacity

Countries

Denmark

Outcome results